Recordati REC.MI
Recordati is an Italian pharmaceutical company specializing in prescription drugs for rare diseases and consumer specialties. Recordati combines a solid moat (ROE 24.85%, gross margin 71.48%) with 28.6% earnings growth and a reasonable valuation (forward P/E 14.13), though momentum is weak (0.77) and Italian governance risk adds a discount.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Recordati is an Italian pharmaceutical company specializing in prescription drugs for rare diseases and consumer specialties. Recordati combines a solid moat (ROE 24.85%, gross margin 71.48%) with 28.6% earnings growth and a reasonable valuation (forward P/E 14.13), though momentum is weak (0.77) and Italian governance risk adds a discount.
Score by category
| Category | Score |
|---|---|
| Financial health | 7.0 |
| Quality / Moat | 7.8 |
| Valuation | 6.5 |
| Growth | 7.3 |
| Dividend | 6.9 |
| Momentum | 3.0 |
| Risk & Context | 6.0 |
OVERALL SCORE: 6.7/10
Context and risks
Italy presents elevated governance risk (weak minority protection and potential political interference), adding a jurisdictional risk discount. Additionally, a potential private equity delisting introduces uncertainty over the final price and treatment of minority shareholders.
News considered in the analysis
- Private Equity Prescribes a Delisting for Recordati — Una posible opa de exclusión a prima por parte de capital privado es un evento material que podría revalorizar la acción; no está confirmado y el mercado solo lo descuenta parcialmente.
- 3 European Stocks That May Be Undervalued In May 2026 — Listículo genérico de acciones infravaloradas sin información específica nueva.
- European Value Stocks Estimated Below Intrinsic Worth In April 2026 — Listículo genérico sin catalizador concreto.
- European Stocks That May Be Undervalued In April 2026 — Listículo genérico sin información accionable.
- 3 European Stocks Estimated To Be Up To 48.1% Below Intrinsic Value — Listículo genérico de valoración sin catalizador.
Verdict: Hold; the fundamental profile is attractive and a potential take-private bid is a catalyst, but governance risk and weak momentum limit near-term upside.
Main risk: Italian governance risk (weak minority protection) and uncertainty over a potential take-private bid at a price that may not reflect intrinsic value.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →